Peter Sandner

Medizinische Hochschule Hannover — Germany

Medicine · Health Sciences

41h-index5.3kcitations226works4.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Nitric Oxide and Endothelin Effects(45), Sexual function and dysfunction studies(44), Urinary Bladder and Prostate Research(43), Phosphodiesterase function and regulation(25), Hormonal and reproductive studies(21)

Publications225 total

Abstract 4357820: Proteomic and Phosphoproteomic Profiling of Cardiac Left Ventricular Tissue from an Animal Model of Early Stage Heart Failure with Preserved Ejection Fraction after Soluble Guanylate Cyclase Stimulation
Circulation·2025
Exploring the potential of soluble guanylyl cyclase stimulators and activators in heart failure
Biochemical Pharmacology·2025Open Access
Soluble guanylate cyclase stimulation improves cardiac function and mitochondrial activity in a rat model of early-stage heart failure with preserved ejection fraction
Biomedicine & Pharmacotherapy·2025· 1 citedOpen Access
Metabolic reprogramming of methylthioadenosine-dependent sulfur recycling is a major driver of CHIKV infection
2025Open Access
Effects of soluble guanylyl cyclase stimulation on muscle oxygenation and exercise capacity in heart failure with mildly reduced ejection fraction
Experimental Physiology·2025Open Access
The treatment with soluble guanylate cyclase stimulator BAY41-8543 prevents malignant hypertension and associated organ damage
Journal of Hypertension·2025· 2 citedOpen Access
Discovery of the first isoform-specific sGC activator: Selective activation of GC-1 by runcaciguat
European Journal of Pharmacology·2025· 1 citedOpen Access
Runcaciguat activates soluble guanylyl cyclase via the histidine essential for heme binding and nitric oxide activation
Biochemical Pharmacology·2025· 2 citedOpen Access
Soluble guanylyl cyclase stimulators and activators: Promising drugs for the treatment of hypertension?
European Journal of Pharmacology·2024· 12 citedOpen Access
Activating soluble guanylyl cyclase attenuates ischemic kidney damage
Kidney International·2024· 16 cited
Real-world evidence for patient phenotypes in heart failure with preserved ejection fraction
European Heart Journal·2024Open Access
The sGC stimulator (BAY41-8543) improves the survival of rats with DOXO-induced HFrEF with nephrotic syndrome
2024Open Access
Metabolic dysfunction-associated steatotic liver disease can be alleviated by activating NO/cGMP signaling
2024Open Access
Discovery of the first isoform-specific sGC activator
2024Open Access
Pharmaceutical activation of soluble guanylate cyclase diminishes acute kidney injury progression to chronic kidney disease
2024Open Access
Biomarker analysis from the phase 2b randomized placebo-controlled trial of riociguat in early diffuse cutaneous systemic sclerosis
Lara D. Veeken·2024· 3 citedOpen Access
The nitric oxide–soluble guanylate cyclase–cGMP pathway in pulmonary hypertension: from PDE5 to soluble guanylate cyclase
European Respiratory Review·2024· 32 citedOpen Access
CASE HISTORY: DISCOVERY AND DEVELOPMENT OF VERQUVO® (VERICIGUAT), A SOLUBLE GUANYLATE CYCLASE (SGC) STIMULATOR FOR THE TREATMENT OF CHRONIC HEART FAILURE
Medicinal chemistry reviews·2023
Soluble guanylyl cyclase: A novel target for the treatment of vascular cognitive impairment?
Pharmacological Research·2023· 16 citedOpen Access
The sGC Activator Runcaciguat Has Kidney Protective Effects and Prevents a Decline of Kidney Function in ZSF1 Rats
International Journal of Molecular Sciences·2023· 13 citedOpen Access
page 1 of 12Next →

Frequent Co-authors

Mario Maggi(7), Johannes‐Peter Stasch(7), Sandra Filippi(6), Annamaria Morelli(6), Benedetta Fibbi(6), Mauro Gacci(6), Linda Vignozzi(6), Gabriella Barbara Vannelli(6), Hanna Tinel(5), Aravinda K. Chavalmane(5), Armin Kurtz(5), Marco Carini(4), Markus Follmann(4), Erica Sarchielli(4), Joachim Hütter(4), Frank Eitner(4), Oliver Distler(4), Jörg H. W. Distler(4), Michael G. Hahn(4), Eva‐Maria Becker‐Pelster(3)